HUTCHMED (China) Ltd（HCM）のニュースとイベント

$14.110

+2.426 (+17.19%)終値時点

HCM のニュース

8.509-03Newsfilter

HUTCHMED Enters Exclusive License Agreement with GSK for HMPL-A830

7.509-03Yahoo Finance

Hutchmed Licenses Drug Development Rights to GSK

9.008-31Newsfilter

HUTCHMED Reports Positive SANOVO Trial Results for Lung Cancer Treatment

9.008-28Newsfilter

HUTCHMED's ATLED Receives Conditional Approval in China

2.008-17Newsfilter

SAFFRON Trial Shows TAGRISSO Significantly Improves Survival Rates

9.507-30seekingalpha

HUTCHMED Reports H1 2023 Financial Results

9.007-02Newsfilter

HUTCHMED Receives Conditional Approval for ORPATHYS® in Gastric Cancer

9.506-30Newsfilter

HUTCHMED to Announce Interim Results on July 30

8.506-25NASDAQ.COM

HUTCHMED's Fanregratinib Meets Primary Endpoint in Phase 2 Study

9.006-25Newsfilter

Fanregratinib Shows Promising Results in ICC Treatment

ニュースをもっと見る

HCM のイベント

9/3 12:30

Stock Up $2.06 to $14.10 in Midday Trading

The stock in midday trading is up $2.06 to $14.10.

9/3 10:30

Hutchmed Stock Rises 13.7% to $13.69

Hutchmed is up 13.7%, or $1.65 to $13.69.

9/3 05:30

Hutchmed Enters Development Agreement with GSK for HMPL-A830

Hutchmed (HCM) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK (GSK), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a $110M upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of $1.3B, and royalties on net sales. Under the terms of the agreement, Hutchmed Limited will be responsible for the global phase I development program, which is expected to start in the second half of 2026. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan.

7/2 05:30

Hutchmed's Orpathys Receives Conditional Approval from NMPA

Hutchmed announced that the new drug application, or NDA, for Orpathys has been granted conditional approval by the China National Medical Products Administration, or NMPA, for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments.

5/21 06:10

Innovent Biologics and Hutchmed Announce New Drug Approval

Innovent Biologics and Hutchmed jointly announce that the new drug application for the combination of Tyvyt and Elunate has been granted approval by the China National Medical Products Administration for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors therapy and have not received programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy in the first-line setting.

イベントをもっと見る

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。